Michael Feldman
Affiliations: | 1955-2005 | Weizmann Institute of Science, Rehovot, Israel |
Area:
cancer research, cellular immunology, developmental biologyWebsite:
https://www.academy.ac.il/Index2/Entry.aspx?nodeId=835&entryId=18279Google:
"Michael Feldman"Bio:
(1926 - 2005)
https://prabook.com/web/michael.feldman/1302406
https://books.google.com/books?id=5Eg71tOCxJoC&lpg=PA43&pg=PA43#v=onepage&q&f=false
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Ruella M, Klichinsky M, Kenderian SS, et al. (2017) Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery |
Posey AD, Schwab RD, Boesteanu AC, et al. (2016) Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 44: 1444-1454 |
Bhoj VG, Arhontoulis D, Wertheim G, et al. (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood |
Wang E, Wang LC, Tsai CY, et al. (2015) Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunology Research. 3: 815-26 |
Tsygankova OM, Ma C, Tang W, et al. (2010) Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion. Molecular and Cellular Biology. 30: 3262-74 |
Carmon L, El-Shami KM, Paz A, et al. (2000) Novel breast-tumor-associated MUC1-derived peptides: Characterization in D(b-)/- x β2 microglobulin (β2m) null mice transgenic for a chimeric HLA- A2.1/D(b)-β2 microglobulin single chain International Journal of Cancer. 85: 391-397 |
El-Shami KM, Tirosh B, Popovic D, et al. (2000) Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide International Journal of Cancer. 85: 236-242 |
Tirosh B, el-Shami K, Vaisman N, et al. (1999) Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunology Letters. 70: 21-8 |
El-Shami K, Tirosh B, Bar-Haîm E, et al. (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope European Journal of Immunology. 29: 3295-3301 |
SELA M, FUCHS S, FELDMAN M. (1998) Specific immunologic unresponsiveness to synthetic polypeptide antigens. Science (New York, N.Y.). 139: 342-3 |